

## **PRESS RELEASE**

**Ad hoc announcement pursuant to article 53 LR**

### **Lepu Medical Technology (Beijing) Co., Ltd.**

#### **Announcement on the 2025 Interim Profit Distribution Plan**

**The Company and all members of the Board of Directors warrant that the information disclosed is authentic, accurate and complete, and contains no false records, misleading statements or material omissions.**

Lepu Medical Technology (Beijing) Co., Ltd. (hereinafter referred to as the Company) convened the 16th meeting of the 6th Board of Directors and the 11th meeting of the 6th Board of Supervisors on August 21, 2025. Both meetings have passed the proposal regarding 2025 Interim Profit Distribution Plan of the Company. This proposal still needs to be submitted to the First Extraordinary General Meeting of 2025 for review. Now, related contents are hereby announced as follows:

#### **I. Deliberative procedures and explanations of relevant opinions**

The benchmark period for this profit distribution plan is the first half of 2025. During this period, the Company achieved operating revenue of RMB 3,369,384,556.21, net profit attributable to shareholders of the listed company of RMB 690,925,899.89, and net profit of the parent company of RMB 393,101,232.38.

In accordance with the relevant provisions of the *Company Law* and the *Articles of Association*, statutory surplus reserve of RMB 39,310,123.24 (10% of the parent company's H1 2025 net profit) has been allocated. The distributable profit for the first half of the year amounts to RMB 353,791,109.14.

The Company maintains a consistent and stable profit distribution policy that balances sustainable development with reasonable investment returns for shareholders. The 2025 interim profit distribution plan is as follows: A cash dividend of RMB 1.6275 per share (tax inclusive) will be distributed to all shareholders based on the total number

of shares on the equity distribution record date (excluding shares held in the Company's repurchase account). No bonus shares will be issued, nor will capital reserve be converted into share capital. As of the Board meeting date, the Company's total share capital stands at 1,880,611,391 shares, with 37,215,700 shares repurchased through centralized bidding transactions and held in the share repurchase account. Based on the total share capital minus repurchased shares, the estimated total cash dividend distribution amounts to RMB 300,012,648.71 (tax inclusive).

From the disclosure date of this cash dividend plan to the record date for its implementation, should there be any changes in the share capital, the distribution will be adjusted based on the revised share capital. The distribution ratio of RMB 1.6275 cash dividend per 10 shares (tax inclusive) will remain unchanged.

This profit distribution plan complies with the relevant provisions of the *Company Law*, *Securities Law*, the *CSRC's No. 3 Regulatory Guidelines for Listed Companies - Cash Dividends*, and the Company's *Articles of Association*. It aligns with the Company's profit distribution policy and shareholder return plan, making the distribution scheme lawful, compliant, and reasonable.

The 2025 interim profit distribution plan has been formulated with due consideration to the company's normal operations and long-term development, taking into comprehensive account factors such as the company's business growth and the interests of investors. This plan enables investors to share in the company's developmental achievements and aligns appropriately with both current operating performance and future growth prospects.

## **II. Precautions of relevant risks**

This profit distribution plan is subject to review and approval by the Company's shareholders' meeting before implementation. As this matter still carries uncertainty, investors are kindly advised to pay attention to investment risks.

## **III. Deliberation Procedures and Relevant Opinion Explanations**

### **1. Board of Directors' Opinion**

The proposal regarding the 2025 Interim Profit Distribution Plan was reviewed and approved at the 16th Meeting of the Sixth Board of Directors. The Board considers

that the 2025 Interim Profit Distribution Plan complies with the Company Law and the Company's Articles of Association, does not harm the interests of shareholders (particularly minority shareholders), is consistent with the Company's financial performance, and aligns with the actual business situation. Accordingly, the Board agreed to submit the 2025 Interim Profit Distribution Plan to the First Extraordinary General Meeting of Shareholders in 2025 for deliberation.

## 2. Supervisory Committee's Opinion

The proposal regarding the 2025 Interim Profit Distribution Plan was reviewed and approved at the 11th Meeting of the Sixth Supervisory Committee. The Committee considers that: the Board has formulated the 2025 Interim Profit Distribution Plan based on the Company's actual operational development, which aligns with the Company's development strategy and current circumstances while balancing shareholders' immediate and long-term interests. This profit distribution plan complies with the relevant regulations including the *Company Law*, *Securities Law*, *CSRC Regulatory Guidelines No. 3 - Cash Dividends of Listed Companies*, and the Company's *Articles of Association*, demonstrating legality, compliance, and reasonableness. Therefore, the Committee approves the Company's 2025 Interim Profit Distribution Plan.

## IV. Additional Notes

Prior to the disclosure of this profit distribution plan, the Company strictly complied with applicable laws, regulations, normative documents, and internal policies by:

## V. Reference documents

1. The resolution of 16th Meeting of the 6th Session of the Board of Directors of the Company;
2. The resolution of 11th Meeting of the 6th Session of the Board of Supervisors of the Company;

It is hereby announced.

Lepu Medical Technology (Beijing) Co., Ltd.

Board of Directors

August 23, 2025